XIENCE V Everolimus Eluting Coronary Stent System USA Post- Approval Study (XIENCE V USA DAPT Cohort) (XVU-AV DAPT).
Phase of Trial: Phase IV
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Aspirin; Clopidogrel; Everolimus; Prasugrel
- Indications Coronary artery disease; Coronary artery restenosis; Coronary stent thrombosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms XVU-AV-DAPT
- Sponsors Abbott Laboratories
- 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Mar 2012 Actual initiation date changed from Jul 2008 to Aug 2009 as reported by ClinicalTrials.gov.
- 20 Mar 2012 Additional lead trial investigators identified as reported by ClinicalTrials.gov.